Evidence map›Paper›PMID 40881709›Full record

SynthesisFrontiers in immunology2025

The predictive role of peripheral serum inflammatory markers NLR, PLR, and LMR in ulcerative colitis and Crohn's disease: a systematic review and meta-analysis.

Shufa Tan, Xiaoqing Yang, Xiaojing Mu, Shuang Liu, Yao Wang, Yuwei Li, Yuhong Bian, Chen Xu

Erratum issuedAbstract readSystematic ReviewMeta-Analysis
In one paragraph

Synthesis in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Shufa TanSchool of Integrative Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
Xiaoqing Yang *Tianjin Institute of Urology, the 2nd Hospital of Tianjin Medical University, Tianjin, China.
Xiaojing Mu *Department of Colorectal Surgery, Tianjin Union Medical Center, The First Affiliated Hospital of Nankai University, Tianjin, China.
Shuang LiuSchool of Integrative Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
Yao WangSchool of Integrative Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
Yuwei LiDepartment of Colorectal Surgery, Tianjin Union Medical Center, The First Affiliated Hospital of Nankai University, Tianjin, China.
Yuhong BianSchool of Integrative Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
Chen XuDepartment of Colorectal Surgery, Tianjin Union Medical Center, The First Affiliated Hospital of Nankai University, Tianjin, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and lymphocyte-to-monocyte ratio (LMR) are peripheral serum markers commonly utilized as cost-effective indicators of inflammation. However, their efficacy as predictors of clinical disease activity in inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD), remains uncertain. To address this ambiguity, we conducted a meta-analysis to evaluate the clinical significance of NLR, PLR, and LMR in patients with IBD. Methods: A comprehensive search was conducted in the PubMed, Embase, Web of Science, and Cochrane databases, with the last search date being October 2024. Baseline values of NLR, PLR, and LMR during active and remission phases, as well as moderate and severe conditions, were analyzed as primary endpoints in patients with IBD compared to healthy populations, using risk ratios (WMD) and corresponding 95% confidence interval (CI) estimates. Results: Twenty-three cohort studies involving 3550 IBD patients and 1010 healthy people were finally included in this meta-analysis. The results of the meta-analysis showed that peripheral serum NLR and PLR were significantly higher in IBD patients than in the healthy population NLR [WMD=1.57,95%CI(1.14,2.01),P<0.001], PLR [WMD=60.66,95%CI(51.68,69.64),P<0.001]; NLR in active versus remission stage of IBD, PLR, LMR had significant differences NLR [WMD=1.50,95%CI(1.23,1.78),P<0.001], PLR [WMD=69.02,95%CI(39.66,98.39,P<0.001], LMR [WMD=-1.14,95%CI(-1.43,-0.86,P<0.001]; IBD active period and remission period NLR, PLR and LMR had significant differences. 0.001]; there were significant differences in NLR and PLR between moderate and severe IBD NLR [WMD=-1.41,95%CI(-2.13,-0.69),P<0.001], PLR [WMD=-112.03,95%CI(-143.87,-80.19),P<0.001]; the diagnostic accuracy of markers in predicting the clinical activity of IBD was relatively good. The diagnostic accuracy of markers in predicting IBD clinical activity was more favorable AUC [ES=0.72,95%CI(0.69,0.75),P<0.001]. Conclusion: In patients with IBD, elevated NLR and PLR are associated with increased disease activity and severity in UC and CD. Conversely, an elevated LMR is linked to reduced disease activity in IBD. Based on diagnostic accuracy results, inflammatory markers NLR and PLR serve as effective biomarkers for assessing IBD activity, thereby providing valuable insights for treatment decisions in IBD patients. However, LMR may not be a reliable independent marker due to conflicting or non-significant results. We anticipate that further high-quality prospective studies will validate our findings in the future. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/, identifier CRD42024608118.

Indexed as

Blood PlateletsColitis, UlcerativeCrohn DiseaseLymphocytesMonocytesNeutrophilsBiomarkersHumansLymphocyte CountPlatelet CountPrognosisBiomarkersdisease activityinflammatory bowel diseaseLMRmeta-analysisNLRPLR

Identifiers

PMID40881709
PMCPMC12381567

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.